Taysha Gene Therapies to Release Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 8
Taysha Gene Therapies (Nasdaq: TSHA) will announce its third-quarter financial results on November 8, 2022, at 8:00 AM ET, alongside a corporate update conference call.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Taysha Gene Therapies (Nasdaq: TSHA) will announce its third-quarter financial results on November 8, 2022, at 8:00 AM ET, alongside a corporate update conference call. The company focuses on developing AAV-based gene therapies for monogenic diseases of the central nervous system. This pivotal-stage organization aims to translate treatments quickly from bench to bedside, leveraging a partnership with UT Southwestern Gene Therapy Program.
Positive
- Upcoming financial results and corporate update on November 8, 2022.
Negative
- None.
Details
News Market Reaction – TSHA
The recorded move for TSHA in the trading session of this news was -3.85%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DALLAS, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it will report its financial results for the third quarter ended September 30, 2022, and host a corporate update conference call and webcast on Tuesday, November 8, 2022, at 8:00 AM Eastern Time.
| Conference Call Details | |
| Tuesday, November 8, at 8:00 AM Eastern Time / 7:00 AM Central Time | |
| Toll Free: | 855-327-6387 |
| International: | 631-891-4304 |
| Conference ID: | 10020611 |
| Webcast: | https://ir.tayshagtx.com/news-events/events-presentations |
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.
Company Contact:
Kimberly Lee, D.O.
Chief Corporate Affairs Officer
Taysha Gene Therapies
klee@tayshagtx.com
Media Contact:
Carolyn Hawley
Evoke Canale
carolyn.hawley@evokegroup.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.